ArticleBMC cancer2025

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.

Zhujun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.